Navigation Links
discharge in Medical Technology

ValueOptions(R) Supports New Hospital-Based Performance Measures to Help Patients Get the Best Treatment for Inpatient and Outpatient Services

... with appropriate justification Post discharge continuing care plan created Post discharge continuing care plan transmitted to next level of care provider upon discharge "Coordination between Inpatient ...

Results and Additional Analyses From Study Show That Corthera's Relaxin for Acute Heart Failure is the Strongest Predictor of Improved Longer-Term Outcomes Following Hospital Discharge When Compared to Other Variables

... independent predictor of improved longer-term outcomes following hospital discharge when compared to other variables. The new analyses of predictors of ... shortening of in-hospital stay and improved longer-term outcomes following discharge when compared to placebo. Corthera's Pre-RELAX-AHF/RELAX-AHF study is a ...

AHRQ-Funded Study Finds Lower Risk of Death and Heart Attack in Patients With Drug-Coated Stent Implants Compared to Those With Bare Metal Stents

... with drug-eluting stents may visit their doctors more often after hospital discharge and may receive prescriptions for drugs and therapies to lower their ... together with Medicare national claims data to capture post-hospital discharge information. The authors call for longer follow-up studies to further ...

Healthy Bones Program Reduces Hip Fractures by 37 Percent, Kaiser Permanente Study Finds

... 4. Develop pre-printed admission sheets and orders. 5. Develop a discharge checklist for fragility fracture patients, and improve your discharge documentation. 6. Set realistic goals and measure what you've done. 7. ...

Thoratec Announces FDA Approval of HeartMate II(R) for Bridge-To-Transplantation

... at one year. -- Eighty four percent of the patients survived to hospital discharge or transplantation. -- Significant improvements were observed ... best practices on patient selection, device implantation and patient discharge and follow-up to ensure optimal patient outcomes. In addition, we are ...

Study Shows That Low-Molecular Weight Heparin (LMWH) was Associated with Reduced Hospital Costs of Venous Thromboembolism (VTE) Treatment Compared with Unfractionated Heparin (UFH)

... are not clear. A retrospective real-world cohort study examining discharge and billing records from the Premier Perspective(TM) database included ... LMWH. Furthermore, VTE-related readmission rates at days 30 and 90 post- discharge were compared for both patient cohorts. Total direct medical costs (US $) ...

Diabetes Experts Issue New Recommendations for Inpatient Glycemic Control - Call for Systemic Changes in Hospitals Nationwide

... the risk for errors and episodes of severe hypoglycemia. The consensus group recommends a multidisciplinary approach for care from admission to discharge from the hospital. "The responsibility for management of hyperglycemia shifts from the health care team to the patient following hospital ...

MedImmune Presents New Data Demonstrating Increased Risk for Medically Attended RSV in Late-Preterm Infants

... and December 31, 2002. The neonatal characteristics evaluated included GA, infant sex, "small for GA" status, oxygen exposure variables, and hospital discharge during the RSV season. The authors noted that further research is needed to determine whether strategies to prevent or mitigate RSV infection ...

Results From Study Show Promising Efficacy and Safety Results for Corthera's Relaxin in Acute Heart Failure

... of patients, prevention of heart failure worsening during hospitalization, shortening of in hospital stay and improved longer-term outcomes following discharge when compared to placebo. John R. Teerlink, M.D., professor of medicine, University of California San Francisco , Director of Heart Failure, ...

SYNTAX Analysis Finds Treatment With TAXUS(R) Express2(TM) Stents More Cost Effective Than Bypass Surgery in Many Patients With Complex Coronary Artery Disease

... PCI than CABG through 12-month follow-up ($35,991 for PCI v. $39,581 for CABG) (p=<0.001). The narrowing in the cost difference between hospital discharge and 12-month follow-up was the result of the cost of repeat revascularization procedures and higher long-term costs of anti-platelet medication in ...

Novexel's NXL104/ceftazidime Combination Commences Second Phase II Clinical Trial in Hospital Patients With Complicated Intra-Abdominal Infections (cIAIs)

... were treated for cIAIs in hospital in the seven major pharmaceutical markets. This estimate is based on national databases providing hospital patient discharge data. NXL104/ceftazidime is being developed to treat hospital infections that are caused by Gram negative bacteria, including those resistant ...

Two-Year Follow-Up Data Demonstrates Preservation of Adequate Mitral Valve Area in Patients Treated with the MitraClip(R) System

... mean MVG increased from 1.7 +/- 0.9 mmHg at baseline to 4.1 +/-2.2 mmHg (p<0.05) at discharge. At 12 months MVG was 3.4 +/-1.6 mmHg (n=50). From discharge to 24 months, there were no significant changes in the mean MVA or MVG. There were no differences in mean MVA or MVG at 12 month follow up between ...

Sosei and NeuroSolutions Present Further Data on NSL-043/SD118 at the Society for Neuroscience 38th Annual Meeting

... now ready for Phase II studies. The data presented demonstrate that NSL-043/SD-118 reverses static allodynia and inhibits spontaneous ectopic discharge in the streptozotocin-induced diabetic neuropathy and chronic constriction injury models of neuropathic hypersensitivity and suggest that this ...

Novexel's NXL104/ceftazidime Combination Commences Phase II Clinical Trial in Hospital Patients With Complicated Urinary Tract Infections

... will be in hospitalized patients with complicated urinary tract infections (cUTIs). From national databases providing hospital patient discharge data(i), Novexel estimates that more than 1.1 million patients were treated for cUTIs in the hospital in the seven major pharmaceutical markets in ...

Novexel Reports Positive Phase II Trial Results With NXL103 in Adult Patients With Community Acquired Pneumonia

... activity against MRSA, NXL103 may offer physicians an important therapeutic option when they switch patients from IV to oral treatment prior to discharge from the hospital." About Novexel Novexel is a speciality pharmaceutical company focused on the discovery and development of novel ...

Regado Biosciences Completes Patient Enrollment for Phase IIa Study of REG1 Anticoagulation System

... of facilitating early sheath removal. Primary procedural success in the trial is defined by the absence of significant bleeding events up to hospital discharge or 48 hours post stenting, and by the absence of death, nonfatal heart attack, or need to repeat revascularization up to day 14. David J. Mazzo, ....

Arpida Announces Review of Iclaprim NDA by FDA Advisory Committee in November 2008

... could be offered not only as an intravenous therapy for hospital use in acute situations, but also as an oral formulation, allowing early patient discharge followed by outpatient treatment. This switch could be a valuable instrument in reducing healthcare costs and enhancing patient comfort. Arpida's ...

Evalve Announces Enrollment Completion of the EVEREST Randomized Study

... or severe mitral regurgitation at 12 months. The primary safety endpoint is freedom from major adverse events (MAE) at 30 days or hospital discharge whichever is longer. Evalve received CE Mark approval for the MitraClip device earlier this year and the first series of patients were recently ...

Arpida Completes Enrolment in Phase II "Intravenous-to-Oral" Switch Trial With Oral Iclaprim

... could be offered not only as an intravenous therapy for hospital use in acute situations, but also as an oral formulation, allowing early patient discharge followed by outpatient treatment. This switch could be a valuable instrument in reducing healthcare costs and enhancing patient comfort. Arpida's ...

High Intensity Focused Ultrasound for Locally Recurrent Prostate Cancer Following External Beam Radiation Therapy Investigated in Phase III Clinical Study

... This investigational treatment is performed on an outpatient basis. Potential risks of the treatment include frequency, urgency, mild discomfort or discharge in urinary stream. Less common side effects may also include urinary stricture, retention, incontinence, impotence and rectal fistula. Prostate ...

Discharge of First U.S. DuraHeart(TM) Patient

... ANN ARBOR, Mich., Aug. 21 /PRNewswire/ Terumo Heart, Inc. today announced the discharge of the first U.S. patient implanted with the DuraHeart(TM) Left Ventricular Assist System (LVAS). The patient was discharged home on August 14th, ...

CryoCath Arctic Front(R) Results Published in JACC

... nerve palsies were reported in 7.5 percent of patients treated; in some instances these were resolved prior to the end of the procedure or hospital discharge and all cases were resolved by the 12-month follow up visit. "This study demonstrates the utility of Arctic Front in effectively isolating the ...

MAP Pharmaceuticals Announces Publication of MAP0004 Study in Current Medical Research and Opinion

... and self administered at home using the company's proprietary Tempo(R) inhaler, a novel pressurized metered dose inhaler that synchronizes the discharge of drug with the patient's breathing cycle. The Tempo inhaler can be optimized for each therapy based on desired delivery, and is designed to ...

AstraZeneca Submits an sNDA for SYMBICORT(R) for the Treatment of Asthma in Children as Young as Age Six

... your browser) (9.) Centers for Disease Control and Prevention. Advance Data from Vital and Health Statistics. 2005 National Hospital discharge Survey. Retrieved on 22 May 2008. http://www.cdc.gov/nchs/data/ad/ad385.pdf . (10.) National Heart, Lung, and Blood Institute. ...

Agennix Initiates A Randomized Double-Blind, Placebo-Controlled Phase 2 Study of Oral Talactoferrin in Severe Sepsis

... as Xigris(R)(1), and will be randomly assigned (1:1) to receive either talactoferrin (1.5 g) or placebo three times a day for up to 28 days or until discharge from the intensive care unit (ICU), whichever occurs first. The primary efficacy endpoint of the trial is 28-day all-cause mortality. Secondary ...

MAP Pharmaceuticals Reports Positive Results From Phase 2a Clinical Trial of Combination Therapy in Adult Asthmatics

... About the Tempo Inhaler MAP Pharmaceuticals is developing the Tempo inhaler, a novel pressurized metered dose inhaler that synchronizes the discharge of drug with the patient's breathing cycle, which can be optimized for each therapy based on desired delivery. It is designed to dispense drug in an ...

Data From Ortho Biotech-Sponsored Studies to be Presented at National Kidney Foundation 2008 Spring Clinical Meetings

... and Length of Stay Sandra Sulsky, M.P.H., Ph.D., ENVIRON International Corporation, Amherst, MA A retrospective analysis of hospital discharge records from the 2004 Nationwide Inpatient Sample of the Hospital Cost and Utilization Project, which comprises approximately 90 percent of ...

Clinical Update - Debio 0614 (Istaroxime) in Acute Heart Failure

... failure (ADHF) syndromes represent a significant public health burden, resulting in 1 million patients hospitalised annually in the US with a post discharge event rate (readmissions/deaths) of 35% at 60 days. Debio 0614 is a first in class luso-inotropic agent with calcium cycling modulating ...

New Trial Presented at AAAAI Reports that the Growth of Children 2-5 Years Old with Year-Round Allergic Rhinitis Continued According to Normal Age-Adjusted Distribution Over a 6-Month Treatment with Nasacort AQ

... updated in 2000. About Allergic Rhinitis Allergic rhinitis is a swelling of the nasal passages, usually accompanied by sneezing, watery nasal discharge and itching of the nose and eyes. This medical condition is caused by an allergic reaction to allergens such as house dust, animal dander, or pollen. ...

Arbios Receives Conditional Approval from the FDA to Initiate Pivotal Clinical Trial for SEPET(TM)

... after a reduction of 2 grades of HE, unless other complications require continued ICU care. Similarly, reduction of HE to grade 0, 1 usually permits discharge from the hospital and management as an outpatient, reducing exposure to antibiotic-resistant organisms in hospitals and eliminating risks associated ...

New Research Shows Masimo Perfusion Index (PI) Effective in the Noninvasive Detection of Congenital Heart Defects (CHD) in Newborns

... and saturation screenings fail, PI may help to accurately detect CHD-enabling life-saving early detection and critical intervention before discharge from the hospital. It has been documented that up to 30% of all deaths from CHD in the first year of life are due to unrecognized cases being ...

Regado Biosciences Initiates Phase IIa Clinical Study of REG1 Anticoagulation System

... and aspirin to inhibit platelet activity. Primary procedural success will be defined by absence of significant bleeding events up to hospital discharge or 48 hours post stenting, and by absence of death, nonfatal heart attack, or need to repeat revascularization up to day 14. The study will be ...

The Lancet Publishes Major Phase 3 Study on Novel Oral Direct Thrombin Inhibitor

... bleeding events started after surgery and before the first dose of dabigatran etexilate. There were no major bleeding events reported after hospital discharge in the dabigatran etexilate groups. Data from frequent liver function monitoring showed that the frequency of increases in liver enzyme ...

Everest Data on Short- and Long-Term Use of Otsuka's Investigational Novel Treatment, Tolvaptan, Published in Journal of the American Medical Association and Featured in ACC's Late Breaking Clinical Trials

... three studies: a long-term outcomes trial evaluating patients after their discharge for a minimum of 60 days of treatment, and two identical, embedded ... two short-term studies, reductions in average body weight at day seven or discharge were statistically significantly different between the tolvaptan group ...

Arpida Announces Promising Results of "First-In-Man" Studies With AR-709

... For cases not requiring hospitalisation and/or to accelerate patient discharge from the hospital, targeted delivery, e.g. via inhalation, could provide a ... acute situations, but also as an oral formulation, allowing early patient discharge and outpatient treatment. This switch should be a valuable instrument in ...

Arpida adds novel antibiotic AR-2474 to its preclinical pipeline

... be offered not only as an intravenous therapy for hospital use in acute situations, but also as an oral formulation, allowing early patient discharge and outpatient treatment. This switch should be a valuable instrument in reducing healthcare costs and enhancing patient comfort. Arpida's third ...

Aquavan (Fospropofol Disodium) Injection Data Presented at Digestive Disease Week 2007

... Test-Revised (HVLT-R(TM)), an instrument that measures verbal learning and memory retention. Measures of time to fully alert (TTFA) and time to discharge (TTD) were also analyzed, and showed that patients who received Aquavan 6.5 mg/kg achieved a TTFA of 6.7 minutes and a TTD of 8.7 minutes. Among ...

Novagali Pharma Presents at AACO the Results of its Pivotal Phase III Clinical Trial of Vekacia in Children Suffering From Vernal Keratoconjunctivitis

... was excellent. Overall improvement of subjective symptoms (burning/stinging, tearing, itching, pain, sticky eyelids, foreign body sensation, mucus discharge and photophobia) was superior to the vehicle for both concentrations of Vekacia(R). For objective signs (conjunctival erythema/hyperhemia, ...
Other Contents
(Date:9/21/2014)... warming, are set to rise again in 2014 - reaching ... per cent projected rise in burning fossil fuels is revealed ... UK by researchers at the Tyndall Centre for Climate Change ... of Engineering, Mathematics and Physical Sciences at the University of ... Summit, where world leaders will seek to catalyse action on ...
(Date:9/21/2014)... California, San Diego, have developed a program that predicts ... of genes based on sequences of DNA. They describe ... human embryonic cells in a paper published in ... our cells have the same blueprint, the same DNA, ... author of the report. "Skin cells protect, nerve cells ...
(Date:9/21/2014)... strains of bacteria have emerged that resist even the ... forms of tuberculosis and staphylococcus, infect more than 2 ... the urgent need for new treatments, scientists have discovered ... decade. , MIT engineers have now turned a powerful ... that can disable any target gene, they have shown ...
Breaking Biology News(10 mins):CO2 emissions set to reach new 40 billion ton record high in 2014 2CO2 emissions set to reach new 40 billion ton record high in 2014 3Program predicts placement of chemical tags that control gene activity 2Battling superbugs 2Battling superbugs 3Battling superbugs 4
(Date:9/21/2014)... 2014 More than a quarter of house ... start in one of two ways. The first type of ... The second type of dryer fire occurs when lint builds ... also catch fire due to malfunctioning electrical systems so if it ... a look!) Here are some ways that you can prevent ...
(Date:9/21/2014)... London, United-Kingdom (PRWEB) September 22, 2014 ... Fergus Sweeney and Dr. Lilliam Rosario as keynote speakers ... Transparency”. Following keynotes from Dr. Ben Goldacre in ... Professor Lord Winston in 2011 , PhUSE again ... professions who are passionate about advancement of clinical information. ...
(Date:9/21/2014)... likely to trigger an allergy to peanuts than raw ... The researchers say that specific chemical changes caused by ... recognised by the body,s immune system, ,priming, the body ... time it sees any peanuts. , The results might ... peanut allergies in the Western world compared to populations ...
(Date:9/21/2014)... 2014 Burnaby Physiotherapists at Absolute PhysioCare ... in order to help them with preventative care. This ... clinic that will help clients understand their problem in ... active participation in the healing process. With higher knowledge ... be able to facilitate the therapy that is initiated ...
(Date:9/21/2014)... Expert witness work is in! That ... its 2014 Expert Witness Fees & Practices Survey. With ... and compensation for qualified and credentialed expert witnesses has ... history. , The nearly 600 experts surveyed reported ... work, an increase of 3.2% from ExpertPages’ 2012 survey. ...
Breaking Medicine News(10 mins):Health News:Restoration Local Offers Tips to Avoid Dryer Fires 2Health News:Restoration Local Offers Tips to Avoid Dryer Fires 3Health News:PhUSE announces Final List of Industry Influencers as Keynote Speakers 2Health News:PhUSE announces Final List of Industry Influencers as Keynote Speakers 3Health News:Dry roasting could help trigger peanut allergy 2Health News:Burnaby Physiotherapists Now Provide Educational Information for Preventative Care 2Health News:ExpertPages 2014 Survey Reports Expert Witness Hourly Fees Record All-Time Highs as Demand for Qualified Experts Continues to Grow 2
Other TagsOther Tags